97It should be noted that the arguments raised by the applicant neither call into question the Commission’s decision to prioritise consumer safety by not waiting for the outcome of the diflubenzuron renewal procedure, nor demonstrate that such a decision is unreasonable and disproportionate.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.